Black Hawk Acquisition (BKHA) vs Kalaris Therapeutics (KLRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kalaris Therapeutics is the larger company by market cap ($59.5 million vs $51.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BKHA | KLRS |
|---|---|---|
| Share price | $12.33 | $2.50 |
| Market cap | $51.21M | $59.51M |
| 1-day change | -5.15% | -2.34% |
| YTD return | — | -70.38% |
| 1-year return | — | -62.06% |
| 5-year return | — | -99.51% |
| P/E ratio (TTM) | 37.36 | — |
| EPS (TTM) | $0.33 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.15 | $11.88 |
| 52-week low | $11.00 | $2.35 |
| Distance from 52-week high | -6.24% | -78.96% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +648.40% |
| Average volume | 5.83K | 252.88K |
| Shares outstanding | 4.15M | 23.80M |
| Employees | — | 20 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Black Hawk Acquisition
BKHA stock →Black Hawk Acquisition Corporation is a blank check company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2023 and is based in Danville, California.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About Kalaris Therapeutics
KLRS stock →Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
BKHA vs KLRS FAQ
Which is bigger, Black Hawk Acquisition or Kalaris Therapeutics?
Kalaris Therapeutics (KLRS) is larger, with a market capitalization of $59.51M compared with $51.21M for Black Hawk Acquisition (BKHA).
Are Black Hawk Acquisition and Kalaris Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.